Literature DB >> 23771315

Synergistic effects of curcumin with emodin against the proliferation and invasion of breast cancer cells through upregulation of miR-34a.

Jiaoli Guo1, Wenping Li, Hongliu Shi, Xinhua Xie, Laisheng Li, Hailin Tang, Minqing Wu, Yanan Kong, Lu Yang, Jie Gao, Peng Liu, Weidong Wei, Xiaoming Xie.   

Abstract

Curcumin, a biphenyl compound derived from rhizome, is a powerful anti-cancer agent. Emodin is an active component isolated from the root and rhizome of Rheum palmatum that has been widely used in traditional Chinese medicine for the treatment of various diseases. Currently, there are no studies examining the effect of curcumin in combination with emodin on tumor cell growth. In this study, we report for the first time that combined curcumin and emodin administration synergistically inhibits proliferation (MTT assay), survival (flow cytometry), and invasion (transwell migration assay) of breast cancer cells. Synergism is determined by the Chou-Talalay method. Moreover, we demonstrate that miR-34a is upregulated by curcumin and emodin. This microRNA helps mediate the anti-tumor effects of curcumin and emodin by downregulating Bcl-2 and Bmi-1. Our results not only provide insight into the mechanism of synergy between curcumin and emodin in breast cancer cells, but also suggest a new and potentially useful approach for breast cancer therapy.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23771315     DOI: 10.1007/s11010-013-1723-6

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  49 in total

1.  Emodin suppresses lipopolysaccharide-induced pro-inflammatory responses and NF-κB activation by disrupting lipid rafts in CD14-negative endothelial cells.

Authors:  Guoquan Meng; Yiyao Liu; Changchun Lou; Hong Yang
Journal:  Br J Pharmacol       Date:  2010-12       Impact factor: 8.739

2.  Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study.

Authors:  Lisa A Carey; Charles M Perou; Chad A Livasy; Lynn G Dressler; David Cowan; Kathleen Conway; Gamze Karaca; Melissa A Troester; Chiu Kit Tse; Sharon Edmiston; Sandra L Deming; Joseph Geradts; Maggie C U Cheang; Torsten O Nielsen; Patricia G Moorman; H Shelton Earp; Robert C Millikan
Journal:  JAMA       Date:  2006-06-07       Impact factor: 56.272

Review 3.  Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies.

Authors:  Ting-Chao Chou
Journal:  Pharmacol Rev       Date:  2006-09       Impact factor: 25.468

4.  MiR-34a inhibits proliferation and migration of breast cancer through down-regulation of Bcl-2 and SIRT1.

Authors:  Laisheng Li; Linjin Yuan; Jinmei Luo; Jie Gao; Jiaoli Guo; Xiaoming Xie
Journal:  Clin Exp Med       Date:  2012-05-24       Impact factor: 3.984

Review 5.  MicroRNA signatures in human cancers.

Authors:  George A Calin; Carlo M Croce
Journal:  Nat Rev Cancer       Date:  2006-11       Impact factor: 60.716

Review 6.  Multitargeting by curcumin as revealed by molecular interaction studies.

Authors:  Subash C Gupta; Sahdeo Prasad; Ji Hye Kim; Sridevi Patchva; Lauren J Webb; Indira K Priyadarsini; Bharat B Aggarwal
Journal:  Nat Prod Rep       Date:  2011-10-06       Impact factor: 13.423

7.  Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial.

Authors:  Andrew Tutt; Mark Robson; Judy E Garber; Susan M Domchek; M William Audeh; Jeffrey N Weitzel; Michael Friedlander; Banu Arun; Niklas Loman; Rita K Schmutzler; Andrew Wardley; Gillian Mitchell; Helena Earl; Mark Wickens; James Carmichael
Journal:  Lancet       Date:  2010-07-06       Impact factor: 79.321

8.  Tumor characteristics associated with mammographic detection of breast cancer in the Ontario breast screening program.

Authors:  Victoria A Kirsh; Anna M Chiarelli; Sarah A Edwards; Frances P O'Malley; Rene S Shumak; Martin J Yaffe; Norman F Boyd
Journal:  J Natl Cancer Inst       Date:  2011-05-03       Impact factor: 13.506

9.  MicroRNA expression profiling of male breast cancer.

Authors:  Matteo Fassan; Raffaele Baffa; Juan P Palazzo; Joshua Lloyd; Marco Crosariol; Chang-Gong Liu; Stefano Volinia; Hannes Alder; Massimo Rugge; Carlo M Croce; Anne Rosenberg
Journal:  Breast Cancer Res       Date:  2009-08-10       Impact factor: 6.466

10.  Curcumin induces cell death in esophageal cancer cells through modulating Notch signaling.

Authors:  Dharmalingam Subramaniam; Sivapriya Ponnurangam; Prabhu Ramamoorthy; David Standing; Richard J Battafarano; Shrikant Anant; Prateek Sharma
Journal:  PLoS One       Date:  2012-02-17       Impact factor: 3.240

View more
  36 in total

Review 1.  MicroRNAs mediate therapeutic and preventive effects of natural agents in breast cancer.

Authors:  Zhipin Liang; Yaguang Xi
Journal:  Chin J Nat Med       Date:  2016-12

2.  MicroRNA-124 inhibits proliferation and induces apoptosis by directly repressing EZH2 in gastric cancer.

Authors:  Liming Xie; Zhiwei Zhang; Zhiqin Tan; Rongfang He; Xi Zeng; Yuanjie Xie; Suyun Li; Guohua Tang; Hailin Tang; Xiusheng He
Journal:  Mol Cell Biochem       Date:  2014-07       Impact factor: 3.396

Review 3.  Effects of resveratrol, curcumin, berberine and other nutraceuticals on aging, cancer development, cancer stem cells and microRNAs.

Authors:  James A McCubrey; Kvin Lertpiriyapong; Linda S Steelman; Steve L Abrams; Li V Yang; Ramiro M Murata; Pedro L Rosalen; Aurora Scalisi; Luca M Neri; Lucio Cocco; Stefano Ratti; Alberto M Martelli; Piotr Laidler; Joanna Dulińska-Litewka; Dariusz Rakus; Agnieszka Gizak; Paolo Lombardi; Ferdinando Nicoletti; Saverio Candido; Massimo Libra; Giuseppe Montalto; Melchiorre Cervello
Journal:  Aging (Albany NY)       Date:  2017-06-12       Impact factor: 5.682

Review 4.  Plant natural modulators in breast cancer prevention: status quo and future perspectives reinforced by predictive, preventive, and personalized medical approach.

Authors:  Sona Uramova; Peter Kubatka; Zuzana Dankova; Andrea Kapinova; Barbora Zolakova; Marek Samec; Pavol Zubor; Anthony Zulli; Vanda Valentova; Taeg Kyu Kwon; Peter Solar; Martin Kello; Karol Kajo; Dietrich Busselberg; Martin Pec; Jan Danko
Journal:  EPMA J       Date:  2018-11-12       Impact factor: 6.543

5.  Evaluation of the Effects of Nanomicellar Curcumin, Berberine, and Their Combination with 5-Fluorouracil on Breast Cancer Cells.

Authors:  Parisa Ziasarabi; Amirhossein Sahebkar; Faezeh Ghasemi
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 6.  The versatile emodin: A natural easily acquired anthraquinone possesses promising anticancer properties against a variety of cancers.

Authors:  Qing Zhang; Wen Wen Chen; Xue Sun; Die Qian; Dan Dan Tang; Li Lin Zhang; Mei Yan Li; Lin Yu Wang; Chun-Jie Wu; Wei Peng
Journal:  Int J Biol Sci       Date:  2022-05-16       Impact factor: 10.750

Review 7.  Anti-Cancer Effects of Dietary Polyphenols via ROS-Mediated Pathway with Their Modulation of MicroRNAs.

Authors:  Yasukiyo Yoshioka; Tomokazu Ohishi; Yoriyuki Nakamura; Ryuuta Fukutomi; Noriyuki Miyoshi
Journal:  Molecules       Date:  2022-06-14       Impact factor: 4.927

Review 8.  Naturally occurring anti-cancer compounds: shining from Chinese herbal medicine.

Authors:  Hua Luo; Chi Teng Vong; Hanbin Chen; Yan Gao; Peng Lyu; Ling Qiu; Mingming Zhao; Qiao Liu; Zehua Cheng; Jian Zou; Peifen Yao; Caifang Gao; Jinchao Wei; Carolina Oi Lam Ung; Shengpeng Wang; Zhangfeng Zhong; Yitao Wang
Journal:  Chin Med       Date:  2019-11-06       Impact factor: 5.455

Review 9.  The comprehensive landscape of miR-34a in cancer research.

Authors:  Sijing Li; Xiaohui Wei; Jinyong He; Quanquan Cao; Danyu Du; Xiaoman Zhan; Yuqi Zeng; Shengtao Yuan; Li Sun
Journal:  Cancer Metastasis Rev       Date:  2021-05-06       Impact factor: 9.264

Review 10.  Impact of Nutrition on Non-Coding RNA Epigenetics in Breast and Gynecological Cancer.

Authors:  Rosanna H E Krakowsky; Trygve O Tollefsbol
Journal:  Front Nutr       Date:  2015-05-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.